---
title: "Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Salvage surgery and reirradiation for locoregional recurrence"
description: "Formulary evidence on Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Salvage surgery and reirradiation for locoregional recurrence. Topics: Recurrent oral cavity cancer: surgery and radiation therapy by initial treatment, Recurrent laryngeal cancer: salvage surgery and reirradiation, Recurrent oropharyngeal cancer: surgical resection and additional radiation therapy, International consensus on reirradiation, and 6 further topics. 10 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description/salvage-surgery-and-reirradiation-for-locoregional-recurrence"
published: "2026-11-15T21:46:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Salvage surgery and reirradiation for locoregional recurrence

<a id="heading-2.2.2.1.6"></a>

## 2.2.2.1.6 Salvage Surgery and Reirradiation for Locoregional Recurrence

<a id="topic-2.2.2.1.6-1"></a>

### Recurrent oral cavity cancer: surgery and radiation therapy by initial treatment

> “Surgery is the preferred treatment if radiation therapy was used initially.”
> “radiation therapy, or a combination of these treatments may be considered if surgery was used to treat the lesion initially.”
> “both surgical salvage after primary radiation therapy and radiation therapy after primary surgery give poor results.”

Source: [National Cancer Institute Lip and Oral Cavity Cancer Treatment PDQ (2025)](https://www.cancer.gov/types/head-and-neck/hp/adult/lip-mouth-treatment-pdq)

<a id="topic-2.2.2.1.6-2"></a>

### Recurrent laryngeal cancer: salvage surgery and reirradiation

> “Salvage is possible for failures of surgery alone or of radiation therapy alone”
> “Selected patients may be candidates for partial laryngectomy after high-dose radiation therapy has failed.”
> “Re-irradiation for laryngeal salvage following radiation therapy failure has resulted in long-term survival in a small number of patients; it may be considered for small recurrences after radiation therapy, especially in patients who refuse or are not candidates for laryngectomy.”
> “Salvage after previous combined total laryngectomy and radiation therapy is poor.”

Source: [National Cancer Institute Laryngeal Cancer Treatment PDQ (2025)](https://www.cancer.gov/types/head-and-neck/hp/adult/laryngeal-treatment-pdq)

<a id="topic-2.2.2.1.6-3"></a>

### Recurrent oropharyngeal cancer: surgical resection and additional radiation therapy

> “The management of metastatic and recurrent carcinomas of the oropharynx is complex and requires multidisciplinary input to establish the optimal treatment.”
> “Surgical resection, if technically feasible and the tumor does not respond to radiation therapy.”
> “Radiation therapy, if the tumor is not completely removed by surgery and curative doses of radiation have not been given previously.”
> “Additional radiation therapy using conventionally fractionated radiation therapy, or hyperfractionated radiation therapy (HFX) with concurrent chemotherapy.”

Source: [National Cancer Institute Oropharyngeal Cancer Treatment PDQ (2025)](https://www.cancer.gov/types/head-and-neck/hp/adult/oropharyngeal-treatment-pdq)

<a id="topic-2.2.2.1.6-4"></a>

### International consensus on reirradiation

> “Reirradiation can be considered for some patients with recurrent or second primary head and neck squamous cell carcinoma arising within previously irradiated regions, a clinical scenario associated with few therapeutic options.”
> “However, evidence remains heterogeneous, and clinical choices are challenged by substantial variability in patient presentation, previous treatments, and toxicity risk.”

Source: [Biau et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42372755/)

<a id="topic-2.2.2.1.6-5"></a>

### Radiation therapy combined with immunotherapy for locoregional recurrence or oligometastatic disease

> “For patients with oligometastatic HNSCC, radiation therapy is safe to give concurrently with immunotherapy for the purpose of palliation or local control, but should not be given to enhance response to immunotherapy outside of a clinical trial (Type: Evidence based, no net benefit; Evidence quality: Moderate; Strength of recommendation: Weak).”

Source: [Yilmaz et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.22.02328)

<a id="topic-2.2.2.1.6-6"></a>

### Salvage surgery versus nonsurgical management: meta-analysis

> “Fifteen studies reported survival for salvage surgery and nonsurgical management of recurrence. Five-year OS ranged from 26% to 67% for the salvage surgery groups, compared to 0% to 32% for the nonsurgical management groups. Six studies reported HRs comparing salvage surgery to nonsurgical management; the pooled HR was 0.25 (95% CI [0.16, 0.38]; p < 0.0001).”

Source: [Bulbul et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34729845/)

<a id="topic-2.2.2.1.6-7"></a>

### Salvage surgery and survival after progression of oropharyngeal cancer

> “p16-positive tumor status (HR, 0.48; 95% CI, 0.31 to 0.74) and receipt of salvage surgery (HR, 0.48; 95% CI; 0.27 to 0.84) reduced risk of death after disease progression”

Source: [Fakhry et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4195851/)

<a id="topic-2.2.2.1.6-8"></a>

### Reirradiation with intensity-modulated radiotherapy: meta-analysis

> “A total of 17 studies involving 1635 patients were included. Fourteen (82%) of those were retrospective, and 15 (88%) were from single institution. Reirradiation with IMRT produced pooled 2-year LC and OS rates of 52% (95% confidence interval [CI], 46%-57%) and 46% (95% CI, 41%-50%), respectively.”
> “The pooled rates of late grade ≥ 3 and grade 5 toxicities were 26% (95% CI, 20%-32%) and 3.1% (95% CI, 2%-5%), respectively.”

Source: [Lee et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32437021/)

<a id="topic-2.2.2.1.6-9"></a>

### Postoperative reirradiation with chemotherapy after salvage surgery: randomized trial

> “Between 1999 and 2005, 130 patients with head and neck cancer were treated with salvage surgery and randomly assigned to full-dose reirradiation combined with chemotherapy (RT arm) or to observation”
> “At 2 years, 39% of patients in the RT arm and 10% in the WS arm experienced grade 3 or 4 late toxicity according to Radiation Therapy Oncology Group criteria (P = .06).”
> “Full-dose reirradiation combined with chemotherapy after salvage surgery significantly improved DFS, but had no significant impact on OS.”

Source: [Janot et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18936479/)

<a id="topic-2.2.2.1.6-10"></a>

### Palliative reirradiation with chemotherapy versus methotrexate: randomized trial

> “Due to a very slow accrual, the trial was closed after inclusion of 57 patients.”
> “re-irradiation did not improve OS compared with methotrexate (23% versus 22% at 1year, NS).”

Source: [Tortochaux et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21741720/)

## Related pages
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Terms and abbreviations](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations.md)
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: References](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references.md)
